Cargando…
Rapid improvements in MADRS with zuranolone in major depressive disorder and postpartum depression: results from the LANDSCAPE/NEST clinical development programmes
INTRODUCTION: Rapid-acting therapies remain an unmet need in the treatment of major depressive disorder (MDD) and postpartum depression (PPD). Zuranolone (ZRN) is being evaluated as a once-daily, oral, 14-day treatment for adult patients with MDD and PPD. OBJECTIVES: To evaluate the efficacy (assess...
Autores principales: | Clayton, A. H., Deligiannidis, K. M., Ramos-Quiroga, J. A., Lasser, R., Sankoh, A. J., Leclair, B., Kotecha, M., Doherty, J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10596067/ http://dx.doi.org/10.1192/j.eurpsy.2023.276 |
Ejemplares similares
-
Clinical Efficacy of a 2-Week Treatment Course of Zuranolone for the Treatment of Major Depressive Disorder and Postpartum Depression: Outcomes From the Clinical Development Program
por: Clayton, A., et al.
Publicado: (2022) -
Effect of Zuranolone vs Placebo in Postpartum Depression: A Randomized Clinical Trial
por: Deligiannidis, Kristina M., et al.
Publicado: (2021) -
A phase 1 double‐blind, placebo‐controlled study of zuranolone (SAGE‐217) in a phase advance model of insomnia in healthy adults
por: Bullock, Amy, et al.
Publicado: (2021) -
Efficacy and safety of zuranolone in major depressive disorder: a meta-analysis of factor effect and dose-response analyses
por: Lin, Yu-Wei, et al.
Publicado: (2023) -
Current pharmacotherapy approaches and novel GABAergic antidepressant development in postpartum depression
por: Carlini, Sara V, et al.
Publicado: (2023)